Since our analysis above revealed that LMP2, PSME1 and PSME2 might play a role in antitumor immunity, we established a retrospective tumor cohort (validation cohort) of 50 patients with NSCLC treated with NACI to further examine our findings. The gene discussed is PSME1; the disease is non-small cell lung carcinoma.